Comparison of mazolam and propofol in controlling agitation during recovery period of general anesthesia

Comparison of the safety and efficacy of remidazolam mesylate and propofol in the control of restlessness during recovery period of general anesthesia in adult patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048629

Enrollment

Unknown

Registered

2021-07-12

Start date

2021-07-12

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence agitation

Interventions

Remazolam group:0.05mg/kg, intravenous injection of ralazolam

Propofol group (P group):Propofol 1mg / kg, intravenous injection

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: There were 100 adult patients with EA after elective general anesthesia, ASA grade I or II, aged 18-75 years.

Exclusion criteria

Exclusion criteria: History of allergy to analgesic or sedative drugs; History of mental illness; History of alcohol or drug abuse; Cognitive impairment or language barrier and unable to communicate; Bradycardia.

Design outcomes

Primary

Measure	Time frame
Restlessness and sedation score;	—

Countries

China

Contacts

Public ContactYuan Jingjing

The First Affiliated Hospital of Zhengzhou University

yjingjing-99@163.com+86 13513719631

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026